Phase 2 Prostate Cancer Trial, Recruiting NCT06927635 Sponsor: University Health Network, Toronto Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06927635
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults older than 18 years of age
  • People who are able to give their informed consent to participate
  • People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma, confirmed by tissue testing)
  • People whose prostate cancer has continued to grow or spread despite having very low testosterone levels (known as castration-resistant prostate cancer)
  • People whose scans show fewer than 10 areas of cancer spread outside the brain
  • People who have been receiving a systemic treatment (a medication that works throughout the body) for more than 3 months
  • People where all areas of cancer spread are in locations that doctors can safely treat with a targeted form of radiation called SBRT
  • People with a general health and activity level that falls within a certain range as measured by a standard medical scale (ECOG score of 0–3, meaning anywhere from fully active to capable of limited self-care — confirm with trial site)

Who may not be able to join:

  • People who have signs that cancer is pressing on the spinal cord
  • People for whom radiation therapy is not considered safe or suitable for medical reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rachel Glicksman, MD, Princess Margaret Cancer Centre - University Health Network

Phone: 416-946-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
8 July 2025
Est. completion
1 June 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Study Feasibility; Change in Prostate-Specific Antigen (PSA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov